Biotech stocks rally as clinical wins, deals and new drug technologies revive the sector

Summary

Biotech stocks are rallying as clinical trial wins, mergers and acquisitions, and new drug technologies revive the sector, according to a CNBC report that also lists the exchange-traded funds and stocks analysts favor for investors looking to play the drug innovation boom.

Timeline

1. CNBC

   24 Oct 2026, 18:56 UTCSource ↗

   CNBC reports that biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector, and lists the ETFs and stocks analysts favor.